Related Experiment Video
Updated: Jan 3, 2026

In vitro Assessment of Aortic Regurgitation Using Four-Dimensional Flow Magnetic Resonance Imaging
Published on: February 25, 2022
Predictors of Progression in Patients With Stage B Aortic Regurgitation
Li-Tan Yang1, Maurice Enriquez-Sarano1, Hector I Michelena1
1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Insights
Progression of aortic regurgitation (AR) stage B to C/D occurred in 21% of patients. Echocardiography monitoring and measuring EROA, RVol, annulus, and sinotubular junction can identify high-risk patients for adverse outcomes.
Area of Science:
- Cardiology
- Echocardiography
- Valvular Heart Disease
Background:
- The natural history of stage B aortic regurgitation (AR) remains largely unknown.
- Understanding AR progression is crucial for timely intervention and improved patient outcomes.
Purpose of the Study:
- To investigate the determinants, rate, and consequences of chronic aortic regurgitation progression.
- To identify predictors of AR progression and associated clinical outcomes.
Main Methods:
- Retrospective analysis of 1,077 patients with chronic AR (≤moderate) from 2004-2017.
- Quantification of AR using effective regurgitant orifice area (EROA) and regurgitant volume (RVol) via serial echocardiography.
- Assessment of progression to ≥moderate-severe AR (stage C/D) and associated clinical events.
Main Results:
- 21% of patients progressed to stage C/D AR over a median follow-up of 4.1 years.
- Annualized progression rates were 4.2 mm²/year for EROA and 9.9 ml/year for RVol in progressors.
- Baseline AR severity and sinotubular junction/annulus dimensions predicted progression; hypertension did not.
- Progressors experienced faster chamber remodeling, functional decline, and increased need for aortic valve/surgery.
- Poor survival was linked to age, comorbidities, functional class, and resting heart rate, not LV end-systolic dimension index.
Conclusions:
- Progression from stage B to C/D AR affects 21% of patients, necessitating monitoring.
- Recommended echocardiography surveillance intervals: 5 years (trivial/mild), 3 years (mild-to-moderate), 1 year (moderate) AR.
- Routine measurement of EROA, RVol, annulus, and sinotubular junction aids in risk stratification for AR progression and adverse events.
Background:
The natural history of stage B aortic regurgitation (AR) is unknown.
Objectives:
This study sought to examine determinants, rate, and consequences of progression of AR.
Methods:
Consecutive patients with ≤moderate chronic AR quantified by effective regurgitant orifice area (EROA) and regurgitant volume (RVol) from 2004 to 2017 who had ≥1 subsequent echocardiogram with quantitation were included.
Results:
Of 1,077 patients (66 ± 15 years of age), baseline trivial/mild AR was noted in 196 (18%), mild-to-moderate AR in 465 (43%), and moderate AR in 416 (39%); 10-year incidence of progression to ≥moderate-severe AR (stage C/D; progressors) was 12%, 30%, and 53%, respectively. At 4.1-year follow-up (interquartile range: 2.1 to 7.2 years), there were 228 progressors (21%), whose annualized progression rates within 3 years before diagnosis of ≥moderate-severe AR were 4.2 mm2/year for EROA and 9.9 ml/year for RVol. Baseline AR severity and dimensions of sinotubular junction and annulus were associated with progression (all p ≤ 0.007); hypertension and systolic blood pressure were not. Progressors had faster chamber remodeling, functional class decline, and more aortic valve/aortic surgery. At medium-term follow-up, 242 patients (22%) died; poor survival was linked to age, comorbidities, functional class, resting heart rate, and left ventricular (LV) ejection fraction (p ≤ 0.003), not LV end-systolic dimension index. Survival after progression to stage C/D AR was associated with LV end-systolic dimension index (adjusted p = 0.02).
Conclusions:
Progression from stage B to stage C/D AR was observed in 21% patients. Repeat echocardiography for trivial/mild, mild-to-moderate, and moderate AR at every 5, 3, and 1 years, respectively, was reasonable. EROA, RVol, annulus, and sinotubular junction should be routinely measured to estimate progression rates and identify patients at high risk of progression, which was associated with adverse consequences.
More Related Videos
04:05Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
14:14Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
Published on: December 11, 2017
Related Concept Videos
Aortic Regurgitation I: Introduction
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic Regurgitation III: Medical Management
Aortic Regurgitation IV: Nursing Management
Mitral Regurgitation III: Medical Management
Mitral Regurgitation II: Clinical Features and Diagnostic Tests